Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Scratching the surface: the processing of pain from deep tissues

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Persistent pain following groin hernia repair: what is the best practice in pain management?

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Prescribing opioids for chronic noncancer pain: predicting response and assessing risk factors

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. The chronobiology of migraine: a systematic review

    Research output: Contribution to journalReviewResearchpeer-review

  2. Opening of BKCa channels causes migraine attacks: a new downstream target for the treatment of migraine

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Opening of ATP sensitive potassium channels causes migraine attacks with aura

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Fremanezumab is a humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide and is approved in Europe for migraine prevention in adults with ≥4 migraine days/month. The Pan-European Real Life (PEARL) study is a 24-month, prospective, observational study of fremanezumab in chronic or episodic migraine. End points include proportion of patients with ≥50% reduction in monthly migraine days during 6 months of treatment (primary); changes in monthly migraine days, disability scores and acute headache medication use; adherence and persistence; and effectiveness in patients switching from another calcitonin gene-related peptide pathway-targeting monoclonal antibody. PEARL is being conducted in approximately 100 centers in 11 European countries (estimated n = 1100). PEARL will generate important real-world data on effectiveness of fremanezumab and treatment patterns in patients with chronic migraine or episodic migraine.

Original languageEnglish
JournalPain Management
Volume11
Issue number6
Pages (from-to)647-654
Number of pages8
ISSN1758-1869
DOIs
Publication statusPublished - Nov 2021

    Research areas

  • adherence, calcitonin gene-related peptide, chronic, episodic, fremanezumab, migraine, persistence, real world

ID: 66500888